United Therapeutics Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| UTH.F | LQDA | VTRS | NBIX | 2096.HK | IPN.PA | |
|---|---|---|---|---|---|---|
| Market cap | 21.30B | 3.48B | 21.23B | 14.37B | 26.58B | 12.50B |
| P/E (TTM) | 20.8 | 27.9 | — | 20.7 | 15.3 | 24.5 |
| Forward P/E | 30.8 | 17.8 | 6.9 | 11.8 | 11.3 | 10.8 |
| Price/book | 3.7 | 17.7 | 1.5 | 3.9 | 2.4 | 2.7 |
| Dividend yield | — | — | 2.60% | — | 1.90% | 1.05% |
| 1-year change | +36.54% | +76.48% | +78.95% | −1.64% | −12.62% | +25.58% |
| Today | +1.33% | −0.06% | +0.16% | +0.02% | −4.51% | −0.33% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All UTH.F news ›FDA clears Phase 2 trial for United Therapeutics’ COPD lung disease treatment
The U.S. Food and Drug Administration has cleared an investigational new drug application, allowing United Therapeutics to proceed with the SUMMIT phase 2 clinical trial of treprostinil SMI in pulmonary hypertension associated with chronic…
United Therapeutics opens third xenograft production facility in Houston
StreetInsider United Therapeutics Corporation (Nasdaq: UTHR) has opened its third Designated Pathogen-Free (DPF) xenograft production facility in Houston, Texas, according to a company statement dated October 20, 2026. Each facility…
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
SCHMID Group Reaches Agreement on Significant Equipment Order to Support HDI Capacity Expansion in Malaysia ASHFORD HOSPITALITY TRUST ANNOUNCES $17 MILLION ADVISORY FEE WAIVER, SHARE PURCHASE COMMITMENT FROM ASHFORD INC. AND TERMINATION OF…
FDA Clears United Therapeutics' SUMMIT Study Of Treprostinil SMI In PH-COPD
United Therapeutics Corp.(UTHR) announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company's investigational new drug application (IND) to proceed with the SUMMIT clinical trial of treprostinil SMI…
United Therapeutics Corporation: Relative Strength Chart - Stock Nasdaq
Compare United Therapeutics Corporation with the company of your choice via a Relative Strength chart. Real-time UTHR price, Nasdaq stock exchange Relative Strength Chart United Therapeutics Corporation All financial news and data tailored…
United Therapeutics Gets FDA Clearance to Start Phase 2 Trial of Treprostinil Soft Mist Inhaler
United Therapeutics said Monday the US Food and Drug Administration cleared its phase 2 trial of an investigational soft mist inhaler version of treprostinil in patients with pulmonary... Published on 10/19/2026 at 08:05 am EDT United…
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
Named for Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, pioneers in xenotransplantation, the biosecure facility is purpose-built to manufacture United Therapeutics’ xenokidneys and xenohearts for its rapidly advancing xeno-organ…
United Therapeutics Corporation Announces FDA Clearance To Proceed With SUMMIT Clinical Trial For Treprostinil SMI In PH-COPD
United Therapeutics Corporation announced that the U.S. Food and Drug Administration has granted clearance under the company?s investigational new drug application to proceed with the SUMMIT clinical... United Therapeutics Corporation…
StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics
Two weeks after 57% plunge, shares surge 25% over three days after companies end six lawsuits that encompassed patent infringement, trade secret, and antitrust claims Two weeks after its stock lost more than half its value following a…
United Therapeutics (NASDAQ: UTHR) general counsel sells 8,300 shares under plan
Posted by Defense World Staff on Oct 19th, 2026 United Therapeutics Corp (NASDAQ: UTHR) EVP and General Counsel Paul A. Mahon sold 8,300 shares on 10/15/2026. The filing puts the price at $541.64 to $546.56 per share, for about $4.52…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
stocktitan.net12
-
marketscreener.com10
-
defenseworld.net7
-
tradingview.com7
-
themarketsdaily.com4
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 95 articles, not a forecast.